CAJ | 학술논문

目的：观察Ⅲ期非小细胞肺癌同步放化疗加巩固化疗的近期疗效及急性毒性反应。方法收治的Ⅲ期NSCLC患者59例,同步加巩固化疗组36例,对照组为序贯放化疗组23例。同步加巩固化疗组：放疗同步2周期化疗,放疗后行2~4周期巩固化疗；序贯组：先行适型放疗,放疗后再行4~6周期化疗。化疗均为TP方案,放疗采用常规分割剂量放射治疗。结果同步放化疗加巩固化疗及序贯组近期有效率分别为61．1%,47．8%(P<0．05),一年生存期率分别为78．3%,54．6%(P<0．05)。主要毒副反应：骨髓抑制,同步组及序贯组分别为100%,73．9%(P<0．05),其他如放射性食管炎,放射性肺炎,胃肠道反应,两者差异无统计学意义。结论同步放化疗加巩固化疗治疗NSCLC较序贯化疗疗效确切,近期局控率高。对于急性毒性反应,如骨髓抑制、放射性肺炎、放射性食管炎及消化道反应,在重组人粒细胞集落刺激因子、适型放疗等支持下,患者多可完成治疗。
목적：관찰Ⅲ기비소세포폐암동보방화료가공고화료적근기료효급급성독성반응。방법수치적Ⅲ기NSCLC환자59례,동보가공고화료조36례,대조조위서관방화료조23례。동보가공고화료조：방료동보2주기화료,방료후행2~4주기공고화료；서관조：선행괄형방료,방료후재행4~6주기화료。화료균위TP방안,방료채용상규분할제량방사치료。결과동보방화료가공고화료급서관조근기유효솔분별위61．1%,47．8%(P<0．05),일년생존기솔분별위78．3%,54．6%(P<0．05)。주요독부반응：골수억제,동보조급서관조분별위100%,73．9%(P<0．05),기타여방사성식관염,방사성폐염,위장도반응,량자차이무통계학의의。결론동보방화료가공고화료치료NSCLC교서관화료료효학절,근기국공솔고。대우급성독성반응,여골수억제、방사성폐염、방사성식관염급소화도반응,재중조인립세포집락자격인자、괄형방료등지지하,환자다가완성치료。
Objective To study the clinical therapeutic effect of concurrent chemo-radiotherapy followed by consolidation chemotherapy ( CCRT-CT) for patients with non-small cell lung cancer at stage Ⅲ. Methods 59 pa-tients with stage Ⅲ non-small cell lung cancer were treated with CCRT-CT and sequential chemo-radiotherapy (SCRT). The CCRT-CT group (36 cases) received 2 cycles of chemotherapy with concurrent radiotherapy followed by 2~4 cycles of chemotherapy. The SCRT group (23 caces) received three-dimensional conformal irradiation fol-lowed by 4~6 cycles of chemotherapy. The chemotherapy consisted of capsulation plus palliate. Radiotherapy was administered three-dimensional conformal irradiation. Results The short-term rate was 61. 1% and 47. 8%, and the 1-year overall survival rate was 78. 3 and 54. 6 respectively in the CCRT-CT group and the SCRT group (P<0. 05). The rate of bone marrow suppression was 100% and 73. 9% respectively in the CCRT-CT group and the SCRT group (P<0. 05). The other acute toxicities included radiation esophagitis, radiation pneumonitis and digestive tract reac-tion ( P>0. 05 ) . Conclusion The effect of CCRT-CT is superior to SCRT in the treatment of patients with non-small cell lung cancer at stageⅢ, with a higher local control rate. In the support of recombinant human granulocyte colony stimulating factor, three-dimensional conformal irradiation, et al, most of the patients can complete treatment.